Clinical Trials Directory

Trials / Recruiting

RecruitingNCT05402072

AMIC Compared With Microfracture for Focal Articular Cartilage Damage of the Hip

Autologous MatRix-Induced ChondrogenEsis ComPared With Microfracture for Focal ArtIcular CaRtilage Damage of the Hip (REPAIR): A Pilot Randomized Controlled Trial

Status
Recruiting
Phase
Phase 1
Study type
Interventional
Enrollment
40 (estimated)
Sponsor
McMaster University · Academic / Other
Sex
All
Age
18 Years – 55 Years
Healthy volunteers
Not accepted

Summary

This is a pilot multi-centre RCT of 40 patients (ages 18-55 years, inclusive) undergoing primary hip arthroscopy with a focal articular cartilage defect of the acetabulum to compare the effect of using autologous matrix-induced chondrogenesis (AMIC) in comparison to microfracture on hip function, health-related quality of life, hip pain, cartilage regeneration, health utility, and any adverse events at 2 years. Follow-up will occur at 6 weeks, 6 months, 12 months, 18 months, and 24 months post-surgery.

Conditions

Interventions

TypeNameDescription
PROCEDUREAutologous matrix-induced chondrogenesis (AMIC)AMIC is a novel approach in which the microfracture technique has been enhanced by the use of a type I/III collagen matrix (Chondro-Gide®; Geistlich Pharma AG, Wolhusen, Switzerland). In this single-step procedure, the matrix is placed over the defect to stabilize the fragile blood clot that arises from microfracture and to provide infrastructure for repair tissue formation. Essentially, the matrix covers the defect and serves as a protective shield that contains the cells and minimizes the impact of shear forces when moving the hip on the delicate blood clot. At the same time, it functions as the roof of a biological chamber that forms over the defect. The biocompatible collagen material provides an environment for cell growth and is replaced by native tissue over time.

Timeline

Start date
2023-03-13
Primary completion
2026-01-01
Completion
2027-01-01
First posted
2022-06-02
Last updated
2025-09-24

Locations

1 site across 1 country: Canada

Source: ClinicalTrials.gov record NCT05402072. Inclusion in this directory is not an endorsement.